Switch theme
Sign up to access all valuation multiples
Daewoong Pharmaceutical Co Ltd develops, manufactures and sells prescription drug products. The company's product portfolio comprises products such as Moxicle, Plunazol Cap, Bearcef tab, Newdizime etc. It develops and promotes brands such as Ursa, Nabota, Luphere, Easyef, Cretropin. The company has manufacturing facilities at Hyangnam and Sungnam.
2002
n/a
LTM Revenue $1.0B
LTM EBITDA $153M
$1.7B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Daewoong Pharmaceutical has a last 12-month revenue (LTM) of $1.0B and a last 12-month EBITDA of $153M.
In the most recent fiscal year, Daewoong Pharmaceutical achieved revenue of $1.0B and an EBITDA of $81.8M.
Daewoong Pharmaceutical expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Daewoong Pharmaceutical valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $1.0B | XXX | $1.0B | XXX | XXX | XXX |
| Gross Profit | $554M | XXX | $534M | XXX | XXX | XXX |
| Gross Margin | 53% | XXX | 52% | XXX | XXX | XXX |
| EBITDA | $153M | XXX | $81.8M | XXX | XXX | XXX |
| EBITDA Margin | 15% | XXX | 8% | XXX | XXX | XXX |
| EBIT | $118M | XXX | $108M | XXX | XXX | XXX |
| EBIT Margin | 11% | XXX | 10% | XXX | XXX | XXX |
| Net Profit | $46.3M | XXX | $18.0M | XXX | XXX | XXX |
| Net Margin | 4% | XXX | 2% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | $395M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Daewoong Pharmaceutical's stock price is KRW 158700 (or $115).
Daewoong Pharmaceutical has current market cap of KRW 1.83T (or $1.3B), and EV of KRW 2.39T (or $1.7B).
See Daewoong Pharmaceutical trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $1.7B | $1.3B | XXX | XXX | XXX | XXX | $4.46 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Daewoong Pharmaceutical has market cap of $1.3B and EV of $1.7B.
Daewoong Pharmaceutical's trades at 1.7x EV/Revenue multiple, and 21.2x EV/EBITDA.
Equity research analysts estimate Daewoong Pharmaceutical's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Daewoong Pharmaceutical has a P/E ratio of 28.7x.
See valuation multiples for Daewoong Pharmaceutical and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $1.3B | XXX | $1.3B | XXX | XXX | XXX |
| EV (current) | $1.7B | XXX | $1.7B | XXX | XXX | XXX |
| EV/Revenue | 1.7x | XXX | 1.7x | XXX | XXX | XXX |
| EV/EBITDA | 11.4x | XXX | 21.2x | XXX | XXX | XXX |
| EV/EBIT | 14.7x | XXX | 16.2x | XXX | XXX | XXX |
| EV/Gross Profit | 3.1x | XXX | n/a | XXX | XXX | XXX |
| P/E | 28.7x | XXX | 73.8x | XXX | XXX | XXX |
| EV/FCF | -574.3x | XXX | -13.5x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialDaewoong Pharmaceutical's last 12 month revenue growth is 5%
Daewoong Pharmaceutical's revenue per employee in the last FY averaged n/a, while opex per employee averaged n/a for the same period.
Daewoong Pharmaceutical's rule of 40 is 18% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Daewoong Pharmaceutical's rule of X is 26% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Daewoong Pharmaceutical and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 5% | XXX | 5% | XXX | XXX | XXX |
| EBITDA Margin | 15% | XXX | 8% | XXX | XXX | XXX |
| EBITDA Growth | 12% | XXX | 12% | XXX | XXX | XXX |
| Rule of 40 | 18% | XXX | 13% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 26% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | n/a | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | 17% | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 12% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 41% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Daewoong Pharmaceutical acquired XXX companies to date.
Last acquisition by Daewoong Pharmaceutical was XXXXXXXX, XXXXX XXXXX XXXXXX . Daewoong Pharmaceutical acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Daewoong Pharmaceutical founded? | Daewoong Pharmaceutical was founded in 2002. |
| Where is Daewoong Pharmaceutical headquartered? | Daewoong Pharmaceutical is headquartered in South Korea. |
| Who is the CEO of Daewoong Pharmaceutical? | Daewoong Pharmaceutical's CEO is Mr. Chang-Jae Lee. |
| Is Daewoong Pharmaceutical publicy listed? | Yes, Daewoong Pharmaceutical is a public company listed on KRX. |
| What is the stock symbol of Daewoong Pharmaceutical? | Daewoong Pharmaceutical trades under 069620 ticker. |
| When did Daewoong Pharmaceutical go public? | Daewoong Pharmaceutical went public in 2002. |
| Who are competitors of Daewoong Pharmaceutical? | Similar companies to Daewoong Pharmaceutical include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Daewoong Pharmaceutical? | Daewoong Pharmaceutical's current market cap is $1.3B |
| What is the current revenue of Daewoong Pharmaceutical? | Daewoong Pharmaceutical's last 12 months revenue is $1.0B. |
| What is the current revenue growth of Daewoong Pharmaceutical? | Daewoong Pharmaceutical revenue growth (NTM/LTM) is 5%. |
| What is the current EV/Revenue multiple of Daewoong Pharmaceutical? | Current revenue multiple of Daewoong Pharmaceutical is 1.7x. |
| Is Daewoong Pharmaceutical profitable? | Yes, Daewoong Pharmaceutical is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Daewoong Pharmaceutical? | Daewoong Pharmaceutical's last 12 months EBITDA is $153M. |
| What is Daewoong Pharmaceutical's EBITDA margin? | Daewoong Pharmaceutical's last 12 months EBITDA margin is 15%. |
| What is the current EV/EBITDA multiple of Daewoong Pharmaceutical? | Current EBITDA multiple of Daewoong Pharmaceutical is 11.4x. |
| What is the current FCF of Daewoong Pharmaceutical? | Daewoong Pharmaceutical's last 12 months FCF is -$3.0M. |
| What is Daewoong Pharmaceutical's FCF margin? | Daewoong Pharmaceutical's last 12 months FCF margin is 0%. |
| What is the current EV/FCF multiple of Daewoong Pharmaceutical? | Current FCF multiple of Daewoong Pharmaceutical is -574.3x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
